9 / 14
Page 25
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
D
ementia is a continuous challenge to medical sciences, a condition with
growing incidence and prevalence all over the world, therefore currently
considered a public health priority by WHO. The results of clinical trials with
recently developed pharmacological resources have demonstrated an evasive
condition. The pathophysiology of dementia has been extensively researched on
a broader scope of possible scenarios to explain the order of events conducting
to this syndrome’s neurodegeneration, and yet dementia is not fully understood.
PubMed, Cochrane, Medline, Sciencedirect, and EBSCO databases were searched
for clinical trials and reviews to assess the available scientific evidence regarding
the efficacy of pharmacotherapy aimed at dementia. Combinations of key words
(free text and MESH terms) were used in the search strategy, including: dementia,
Alzheimer’s disease, treatment, beta amyloid, tau hyperphosphorilation,
intrinsically disordered proteins, oxidative stress, active immunization, passive
immunization, multi-target clinical trials, and systematic reviews. 210 studies
were retrieved. The analysis of the current results is a complex task within a
multi-faceted syndrome. Dementia involves a broad spectrum of diseases
which share specific hallmarks, but have variable developmental pathways.
Revisiting the current, apparently disappointing results that actually represent
labour of years of intensive dedication, it offers us tools and opportunities to
improve the understanding of the pathophysiology, and broaden our perspective.
The objective of this review is to clarify the understanding of the process that
leads to these conditions. Previous results can help us to visualize paradigms
of the pathophysiology, to improve the management of dementia and the
comprehension of an apparently fluctuating pattern of events. Due to its
complexity, the compelling awareness of a change in medical practice towards a
more person-suited and simultaneously, indeed multidisciplinary diagnosis and
management, but integrative of the person as a whole, a more preventive attitude,
and further research towards a multi-target directed pharmacological approach
for treatment, is constantly growing.
Biography
Luis Angel Francisco Sorroza Lopez completed medical
school at age 26 at Universidad Regional del Sureste,
Medical School, in Oaxaca, Mexico, and master studies in
Clinical Pharmacology at La Salle University, Mexico, School
of Chemical Science. He received first prize in the category
of master level Health Sciences (2015) from this current
University, and has been speaker at the 5
th
International
Congress of Dementia and Alzheimer in London (2016) and
the 1
st
. International Neurology Congress in Rome 2018, and
published the correspondent article.
sorrozalopezdr@gmail.comReview of recent pharmacological therapeutics in dementia:
experience and challenges towards a multidisciplinary perspective
Luis-Angel Francisco Sorroza-Lopez
1
Laura Martino-Roaro
2
, Arely Vergara-Castañeda
3
1,2,3
Grupo de Investigación en Ciencias Básicas y Clínicas de la Salud. Facultad de Ciencias
Químicas. Universidad La Salle México
Luis-Angel Francisco Sorroza-Lopez et al., J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-002